« Return to News | Drug Sponsors

Biocon and Pfizer conclude commercialization agreement

Thursday, March 15, 2012 06:01 AM

India-based biotech Biocon and Pfizer have concluded their alliance to commercialize Biocon's biosimilar versions of insulin and insulin analog products.

The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interests to move forward independently. As of March 12, 2012, all rights licensed to Pfizer reverted to Biocon, and all insulin distributed under the brand name Univia and Glarvia were commercially available, exclusively manufactured, supplied, marketed and supported by Biocon.

"Biocon remains committed to delivering its biosimilar insulin portfolio to global markets in its endeavor to make a difference to diabetic patients across emerging and developed economies,” said Kiran Mazumdar Shaw, chairman and managing director, Biocon. “Biocon will continue to work with its existing partners in several markets and will pursue a commercial strategy on its own and through new alliances in other markets."

"In addition, [Pfizer] will continue to be active in our own research and business development efforts for diabetes, which represents a huge unmet medical need, and we remain committed to seeking new solutions to help physicians and patients,” said Diem Nguyen, general manager of biosimilars, Pfizer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.